A high HE4 result deserves careful follow-up, not an automatic cancer conclusion. The number only becomes useful when read alongside kidney function, menopausal status, imaging and the reason the test was ordered.
- High HE4 levels can occur with ovarian malignancy, but chronic kidney disease, smoking, age and some non-gynaecologic illnesses can also raise the result.
- Common assay cutoffs are about 70 pmol/L before menopause and 140 pmol/L after menopause, although laboratories and assay methods differ.
- Kidney function matters: HE4 rises as eGFR falls, so an elevated HE4 with eGFR below 60 mL/min/1.73 m² needs particularly cautious interpretation.
- ROMA score combines HE4, CA-125 and menopausal status for women with an adnexal mass who are being evaluated for surgery; it is not an ovarian-cancer screening test.
- No HE4 blood test can diagnose ovarian cancer alone; ultrasound or other imaging and specialist assessment determine the next step.
- A normal HE4 does not rule out ovarian cancer, especially early-stage disease or tumour types that produce little HE4.
- جىددىي ئالامەتلەر include rapidly progressive abdominal swelling, severe pelvic pain, breathlessness, vomiting or reduced urine output.
- يۈزلىنىش ۋە ئەھۋال usually matter more than one isolated HE4 value measured at a different laboratory or with a different assay.
What an elevated HE4 result means in plain language
An elevated HE4 result does not mean you have ovarian cancer. HE4 is a protein marker that can rise with certain ovarian cancers, but it also rises when kidney filtration is reduced and in several non-cancer settings. In my clinical experience, the first useful question is not “How high is it?” but “Why was it measured, and what do the creatinine, eGFR and scan show?”
HE4, also called WFDC2, is measured in picomoles per litre (pmol/L) and is mainly used when a clinician is assessing a pelvic or adnexal mass. A result above a laboratory flag is a signal to assess context, not a diagnosis. Dr. Thomas Klein, Kantesti’s Chief Medical Officer, has seen many anxious patients whose modest HE4 rise was explained by an eGFR of 45 mL/min/1.73 m² rather than cancer.
The clinical concern rises when high HE4 occurs alongside a suspicious pelvic ultrasound, a rising CA-125, persistent symptoms and a postmenopausal presentation. In contrast, HE4 of 95 pmol/L in a premenopausal person with stable imaging and reduced kidney function has a very different pre-test probability. Our CA-125 symptom guide explains why neither marker should be read in isolation.
كانتېستى بىر AI قان تەكشۈرۈش ئانالىزچىسى that places HE4 beside renal markers, age, reported sex, menopausal status and the laboratory’s own reference interval. That structured comparison can identify a follow-up question; it cannot replace an examination, ultrasound or gynaecology referral.
The most useful first step
Ask for the exact HE4 value, unit, laboratory reference interval, creatinine, eGFR, CA-125, menopausal status and the indication for testing. Those seven details change the interpretation far more than a red “high” flag alone.
What the HE4 blood test measures and when doctors use it
The HE4 blood test measures a secreted protein called human epididymis protein 4, encoded by the WFDC2 gene. It is used primarily to help estimate malignancy risk in an existing adnexal mass, rather than to find cancer in healthy people without symptoms.
Laboratories measure HE4 using automated immunoassays, and the numbers are not perfectly interchangeable between manufacturers. A value of 80 pmol/L from one method should not be treated as identical to 80 pmol/L from another without checking the report. This is one reason a trend is most reliable when samples use the same laboratory and method.
HE4 is expressed in several normal tissues and may be overexpressed by many epithelial ovarian cancers, particularly serous and endometrioid types. It is less helpful for mucinous tumours and some early-stage cancers. A normal result therefore reduces neither symptoms nor imaging findings to “nothing.”
Kantesti نىڭ قان بىئوماركىر يېتەكچىسى distinguishes a tumour marker from a diagnostic test: the former changes probability, while the latter may require imaging, histology and specialist review. That distinction prevents a surprisingly common misunderstanding after patient-portal results arrive before a clinician calls.
HE4 reference ranges: why 70 and 140 pmol/L are not universal
Many laboratories use HE4 cutoffs near 70 pmol/L before menopause and 140 pmol/L after menopause, but these are assay-specific decision thresholds rather than universal normal ranges. Your report’s stated reference interval takes precedence over an internet number.
The widely used 70 and 140 pmol/L thresholds arose from validation work for specific HE4 assays and risk algorithms. They are practical decision aids, not biologic cliffs. A result of 72 pmol/L is not meaningfully different from 68 pmol/L if sample variation, eGFR and assay uncertainty are considered.
Postmenopausal reference limits are higher partly because HE4 increases with age even without cancer. Some European laboratories use age-adjusted upper limits rather than one postmenopausal cutoff. When I review a value just above range, I want the actual age, renal indices and prior value before recommending any conclusion.
A laboratory high flag simply means the result exceeded that laboratory’s reference population. For a broader explanation of flags, see نورمالسىز دائىرىدىن چىققان نەتىجىلەرنىڭ نېمىدىن دېرەك بېرىدىغانلىقى.
Why reduced kidney function can raise HE4 substantially
Reduced kidney filtration is one of the strongest non-cancer reasons for high HE4 levels. HE4 is cleared in part through the kidneys, so concentrations commonly rise as eGFR declines, sometimes well above standard postmenopausal cutoffs.
eGFR دىن تۆۋەن بولسا CKD نى كۆرسىتىدۇ؛ persisting for 3 months meets the usual definition of chronic kidney disease, and this degree of reduction can materially distort HE4 interpretation. In advanced chronic kidney disease, HE4 may reach several hundred pmol/L without ovarian cancer. The relationship is strong enough that renal function should be on every HE4 request review.
Creatinine can be misleading in people with very low or very high muscle mass, dehydration or recent intense exercise. A 58-year-old patient with HE4 of 180 pmol/L and creatinine 1.4 mg/dL may need an eGFR review before anyone interprets the marker as gynaecologic. Read more about chronic kidney disease staging before attributing a renal-associated elevation to cancer.
كانتېستى بىر AI لابراتورىيە سىنىقىنى چۈشەندۈرۈش مۇلازىمىتىدە ئېلان قىلىنىدۇ that reads HE4 with creatinine, eGFR, urea and urine findings rather than generating a cancer label from one protein. A falling eGFR alongside a rising HE4 is often a renal signal first, though concerning symptoms or imaging still require separate assessment.
Benign and non-cancer causes of high HE4 levels
High HE4 levels can result from kidney impairment, older age and cigarette smoking, and they may rise in some chronic pulmonary, cardiac or inflammatory conditions. Benign gynaecologic conditions generally affect HE4 less than CA-125, but “less often” does not mean “never.”
Smoking is independently associated with higher HE4 concentrations, so documenting current smoking status is clinically relevant. Age also shifts the expected range upward, especially after menopause. These effects are usually modest compared with severe renal impairment, but they can explain a borderline result around 75 to 110 pmol/L.
Endometriosis, fibroids and menstruation frequently raise CA-125 more than HE4; that difference is one reason clinicians sometimes order both markers. Yet symptoms such as cyclical pelvic pain still deserve a clinical assessment, regardless of a reassuring HE4. Our review of when CA-125 is high covers the overlap and the limits.
Medication lists matter indirectly. Diuretics, SGLT2 medicines and acute illness can change hydration or kidney indices, while lithium can affect renal function over time; see our guide to لىتىي قوبۇل قىلىش ، بىزنىڭ لىتىي تەكشۈرۈشىمىز. I would not stop a prescribed medicine because of HE4 without speaking to the prescriber.
How menopause, age and smoking change HE4 interpretation
Menopausal status changes both the expected HE4 range and the way ROMA calculates risk. A 55-year-old who has had no periods for 18 months is not interpreted by the same cutoff logic as a 35-year-old with regular cycles.
Most laboratories define menopause clinically—usually 12 consecutive months without a menstrual period when no other cause is present—not by a single FSH result. Surgical menopause, hormonal contraception and hormone therapy can complicate classification. If the laboratory used the wrong menopausal category, the calculated ROMA risk can be misleading.
A practical example: HE4 of 85 pmol/L may be flagged high against a 70 pmol/L premenopausal threshold but fall below a common 140 pmol/L postmenopausal threshold. That does not make either person “safe” or “unsafe”; it changes the background probability and the appropriate pathway.
Cigarette smoking should be recorded honestly because it can nudge HE4 upward and may avert unnecessary alarm. Menopausal hormone therapy does not reliably explain a high HE4, so I would still check renal function and imaging context. For cycle-related lab variation, our ئاياللارنىڭ ھورمون يېتەكچىسى پايدىلىق ئارقا كۆرۈنۈش بىلەن تەمىنلەيدۇ.
What the ROMA score can and cannot tell you
ROMA combines HE4, CA-125 and menopausal status to estimate the likelihood that an existing adnexal mass is malignant. It is intended to help triage women already planned for surgery or specialist evaluation, not to screen the general population.
ROMA uses different equations before and after menopause, then reports a percentage risk based on the assay and laboratory. Common manufacturer cutoffs vary; examples include roughly 11% to 13% before menopause and 25% to 30% after menopause. A percentage above a cutoff prompts specialist-level assessment, not a statement that cancer is present.
Moore et al. evaluated ROMA in women with pelvic masses and showed that combining HE4 and CA-125 could help identify women needing gynaecologic-oncology referral (Moore et al., 2011). That evidence does not establish ROMA as a population screening tool, because predictive values collapse when the disease is rare in the tested group.
كانتېستى بىر AI بىئوماركر ئىزاھلاش سۇپىسى that can explain a reported ROMA calculation, but it does not calculate a diagnosis or overrule the ordering clinician. For patients already treated for a malignancy, tumour-marker trends after treatment need the same caution: trend is useful only within a defined clinical plan.
Why HE4 or ROMA cannot diagnose ovarian cancer alone
HE4 and ROMA cannot diagnose ovarian cancer because neither test identifies a tumour’s location, cell type or stage. Diagnosis requires synthesis of symptoms, pelvic examination, imaging and, when needed, tissue confirmation after appropriate specialist planning.
A blood marker can be high from impaired clearance, another organ condition or assay variation, while a cancer can produce a normal marker. This bidirectional limitation is exactly why tumour markers are poor standalone tests. The absence of a high HE4 should never delay investigation of a clearly concerning ultrasound.
The U.S. Preventive Services Task Force recommends against screening asymptomatic average-risk women for ovarian cancer with CA-125, ultrasound or other screening strategies because harms from false positives outweigh proven benefit (USPSTF, 2018). HE4 and ROMA do not change that recommendation for average-risk screening.
An elevated HE4 should therefore be framed as a risk-modifying clue, not a verdict. Patients with a strong inherited-risk history may need a separate genetics and prevention discussion; our guide to family history and cancer tests explains what routine blood work cannot provide.
What clinicians usually check after high HE4 test results
After a high HE4 result, clinicians usually verify kidney function, review symptoms and arrange or review pelvic imaging if there is a mass or concerning presentation. The next test is driven by the original reason HE4 was ordered, not by a universal one-size-fits-all algorithm.
A sensible first review includes the laboratory method, HE4 value and date, CA-125, creatinine, eGFR, urinalysis, smoking status, menopausal status, medicines and prior imaging. If renal function has changed quickly, repeat renal testing may be more informative than repeating HE4 immediately. Our ئاساسىي ماددا ئالماشتۇرۇش تاختىسى (basic metabolic panel) يېتەكچىسى explains the companion tests.
Transvaginal ultrasound is commonly the first imaging study for an adnexal mass because it assesses morphology, solid areas, septations, fluid and blood flow characteristics. Imaging descriptors and symptoms generally carry more actionable information than a small marker change. MRI or CT is selected by the treating team when ultrasound leaves uncertainty or staging is needed.
As Dr. Thomas Klein, I would ask for a clear written plan: who owns the follow-up, which result will trigger referral and when you will hear back. This is more useful than being told merely to “watch it.”
Symptoms that need faster assessment regardless of the HE4 number
Severe or worsening pelvic or abdominal symptoms need prompt medical assessment even if HE4 is normal. A marker result should never be used to explain away acute pain, increasing abdominal size, vomiting, breathlessness or reduced urine output.
Seek urgent same-day care for sudden severe lower abdominal pain, fainting, persistent vomiting, fever with pelvic pain, new breathlessness, or rapidly enlarging abdominal distension. These symptoms can reflect torsion, obstruction, fluid accumulation, infection, kidney injury or other conditions that require timely examination. They are not specific to cancer.
Book a prompt but non-emergency appointment for bloating or pelvic or abdominal pain occurring more than 12 days per month, early satiety, urinary urgency or unintentional weight loss that persists for several weeks. Frequency and change from your usual baseline matter more than one isolated bad day.
Heavy periods can cause fatigue and iron deficiency while obscuring the broader symptom story; our review of كۆپ مىقداردا ھەيز كېلىش (ئېغىر ھەيز قاناش) explains when bleeding itself needs urgent care.
When repeating an HE4 test helps—and when it adds noise
Repeating HE4 is most useful when the first result may have been influenced by acute kidney change, laboratory variation or an unresolved clinical question. It is least useful when repeated without a plan, especially across different laboratories and assay platforms.
If a repeat is planned, use the same laboratory where possible and repeat creatinine and eGFR on the same date. A difference of 10 to 20 pmol/L near a threshold can fall within ordinary biological and analytical variation. A large persistent rise—particularly with stable renal function and changing imaging—carries more weight.
Do not attempt to lower HE4 through detoxes, fasting or supplements before a repeat. These actions can change hydration and creatinine without addressing the underlying question. A well-hydrated routine sample, taken when you are not acutely unwell if clinically safe to wait, is generally more interpretable.
Kantesti نىڭ ئۇزۇن مۇددەتلىك تەجرىبىخانا تەھلىلى compares dates and companion markers so that a genuine trajectory is easier to distinguish from a different laboratory’s reference range.
HE4 after ovarian cancer treatment: why your own baseline matters
In people treated for ovarian cancer, HE4 may be followed as one component of surveillance when the treating oncology team has established that it tracked the individual’s disease. A rising result alone still does not prove recurrence or determine treatment.
A useful surveillance marker is one that was elevated before treatment, fell with response and is measured consistently afterward. If HE4 was never elevated at diagnosis, it is unlikely to become a reliable personal recurrence marker. CA-125, symptoms, examination and imaging may be more informative depending on the tumour type.
A single value above the laboratory interval can reflect eGFR decline, infection, fluid shifts or assay change. Oncology teams often confirm an unexpected rise and consider the rate of change before arranging imaging. This avoids treating a laboratory fluctuation rather than a person.
Other tumour markers have similar limitations; compare the logic in our CA 19-9 result guide. Surveillance plans should be agreed with the oncology team, not constructed from online cutoff tables.
How to use an AI explanation of HE4 results safely
An AI explanation is safest when it identifies missing context, explains terminology and flags questions for a clinician rather than declaring cancer risk from an isolated result. It should show its assumptions, including the laboratory range and kidney-function data used.
Kantesti AI interprets HE4 results by checking the reported unit, assay interval, CA-125, creatinine, eGFR and time trend before presenting a patient-friendly explanation. Our system is designed to say when a report lacks the information needed for meaningful interpretation. That restraint is clinically safer than confident pattern-matching.
Before uploading any report, remove unnecessary identifiers and confirm that the optical reading captured decimal points, units and reference intervals correctly. A value of 14.0 versus 140 pmol/L produces an entirely different discussion. Our PDF يوللاش توغرىلىقىنى تەكشۈرۈش تىزىملىكى covers common transcription problems.
Kantesti نىڭ كلىنىكىلىق دەلىللەش ئۇسۇلىمىز describes why AI-generated lab explanations require medical oversight and why urgent symptoms should bypass digital interpretation. A clear explanation can reduce panic; it must not delay care.
Questions to bring to your appointment after a high HE4 result
The best appointment questions establish whether HE4 was ordered for a mass, what your kidney function was that day and what specific follow-up is planned. A focused list often turns an alarming laboratory flag into a manageable clinical conversation.
Ask: “Which HE4 assay and reference range did my laboratory use?” “What were my creatinine and eGFR?” “Was I classified as premenopausal or postmenopausal correctly?” and “Do my symptoms or imaging findings change the concern?” Each question addresses a separate source of false reassurance or false alarm.
Also ask whether a repeat should use the same laboratory, whether CA-125 is clinically appropriate, and whether a gynaecologist or gynaecologic oncologist should review the scan. If you have a family history of ovarian, breast, pancreatic or prostate cancer, ask whether genetic counselling is relevant. The Kantesti olumbe omukugu supports our clinician-reviewed standards for these high-stakes interpretation pathways.
As of September 18, 2026, there is no HE4 cutoff that safely substitutes for clinical judgment. The right next step is the one that accounts for your symptoms, renal function, imaging and personal risk—not the one that reacts most strongly to a red flag.
دائىم سورايدىغان سوئاللار
گېنىكولوگىيەلىك راكنىڭ قانچىلىك دەرىجىسىنى HE4 كۆرسىتىدۇ؟
بىرلا CE4 سەۋىيىسى بىلەن تۇخۇمدان راكىنى ھەمىشە ئېنىق بىلدۈرگىلى بولمايدۇ. ئادەتتىكى سىنىمەن قوبۇل قىلىنغان سۇنۇش سۇيىقەستى مېنوتتىن بۇرۇن تەخمىنەن 70 pmol/L, مېنوتتىن كېيىن 140 pmol/L ئەتراپىدا، ئەمما بۆرەك ئىقتىدارىنىڭ قالايمىقانلىشىشى CE4 نى راكتىن باشقا سەۋەبلەرمۇ بۇ قىممەتلەردىن ئاشۇرالايدۇ. 300 pmol/L دىن ئاشقان قىممەتلەر ئادەتتە ئالاھىدە تەكشۈرۈشنى تەلەپ قىلىدۇ، بولۇپمۇ ئېغىزدىكى گۇمانلىق توپ بار بولسا، گەرچە ئۇلار يەنىلا ئېنىق دىياگنوز قويغىلى بولمايدۇ. رەسىملىك تەكشۈرۈش ۋە كلىنىكلىق باھالاش راك بارلىقىنى ئېنىقلايدۇ.
بۆرەك كېسەللىكى خېلىلا يۇقىرى HE4 سەۋەبى بولالامدۇ؟
شۇنداق, خرونىك تۇنجۇق كېسەللىكى HE4 سەۋىيىسىنى زور دەرىجىدە ئۆستۈرەلەيدۇ, چۈنكى سۈزۈش مىقدارىنىڭ تۆۋەنلىشى HE4 نىڭ پاكىزلىنىشىنى ئازايتىدۇ. 60 مىللىلېتىر/مىنۇت/1.73 m² تىن تۆۋەن eGFR چۈشەندۈرۈشكە تەسىر قىلىدۇ, تۇنجۇقنىڭ ئىلغار زىيىنى تۇخۇم 100pmol/L دىن يۇقىرى HE4 قىممىتىنى ھاسىل قىلسا بولىدۇ. كرېئانتىن ۋە eGFR لەرنى HE4 نەتىجىسى بىلەن ئوخشاشلا تەكشۈرۈش كېرەك. يۇقىرى HE4 نەتىجىسىنى تۇنجۇقنىڭ ئىقتىدارىدىن ئايرىپ چۈشەندۈرۈشكە بولمايدۇ.
Yaşlı bir kadında normal HE4 seviyesi nedir?
ياشتىن ئۆتكەن ئاياللار ئۈچۈن دائىملىق ئىشلىتىلىدىغان HE4 چېكى 140 pmol/L، گەرچە توغرا پايدىلىنىش ئارىلىقىنى سىنىقنى ئېلىپ بارغان تەجرىبىخانا بېسىپ چىقارغان. ياش، تاماكا چېكىش ئەھۋالى ۋە بولۇپمۇ بۆرەك ئىقتىدارى مۆلچەردىكى قىممەتنى ئۆزگەرتەلەيدۇ. 140 pmol/L دىن تۆۋەن نەتىجە ئىس-تۈگۈل راكنى رەت قىلمايدۇ، 140 pmol/L دىن يۇقىرى نەتىجە ئۇنى دىئاگنوز قويمايدۇ. نەتىجە جىسمانىي كېسەللىك بىلەن ئۆسمە ئۆسمىسى ۋە CA-125 بىلەن بىرلەشتۈرۈلگەندە ئەڭ پايدىلىق.
ROMA تۇخۇمدان ھۈجەيرە خigenesini диагноз قىلالامدۇ؟
ياق، ROMA تۇخۇمدان راكنى دىئاگنوز قىلالمايدۇ. ROMA نىڭ HE4، CA-125 ۋە مېنوپاز ھالىتىنى بىرلەشتۈرۈپ، بار بولغان جىنسىي ئەزا ماسسىسىنىڭ يامان سۈپەتلىك بولۇش خېۋىنى مۆلچەرلەيدۇ، ئادەتتە يوللىنىش ۋە ئوپېراتسىيە پىلانىنى قوللاش ئۈچۈن. ROMA نىڭ ئورتاق چېكى مۇمكىن بولغان سىناق ۋە مېنوپاز ھالىتىغا ئوخشىمايدۇ، كۆپىنچە مېنوپازدىن بۇرۇنقى 11% دىن 13% غىچە ۋە مېنوپازدىن كېيىنكى 25% دىن 30% غىچە. بۇ خۇرۇچ بېلىۋېرىش سىنىقى ئۈچۈن ئىسپاتلانمىغان.
Endometriosis HE4 نى ئۆستۈرەلەمدۇ؟
Endometriosis بەزەن HE4 نى يۇقىرى كۆتۈرۈشى مۇمكىن، گەرچە CA-125 نىڭ Endometriosis دا HE4 تىن كۆپرەك ئېشىپ كېتىشى تېخىمۇ كۆپ ئۇچرايدۇ. نورمال HE4 Endometriosis نى رەت قىلمايدۇ، ۋە ئازراق يۇقىرى HE4 تۇخۇمدان راكىنى ئورنىتىپ بەرمەيدۇ. بۆرەك ئىقتىدارى، تاماكا چېكىش، ياش ۋە تەسۋىرلەش مەيلى Endometriosis غا قارىغاندا نەتىجىنى چۈشەندۈرۈپ بېرىدۇ. ئۈزلۈكسىز ھەيز قېنىش ئاغرىقى، ئاغرىقلىق ھەيز كېلىش ياكى تۇغۇتتىن ئەنسىرەش ماركېر نەتىجىسىدىن قەتئىي نەزەر گىنىكولوگىيەلىك تەكشۈرۈشنى تەلەپ قىلىدۇ.
يۇقىرى HE4 ئىمۇنىتېستىنى تەكرارلىساممۇ؟
بۆيرەك ئىقتىدارى ئۆزگەرگەندە، ئۆتكۈر كېسەللىك ۋاقتىدا ئەۋھاپ ئېلىنغاندا ياكى نەتىجە كىلىنكىلىق رەسىمگە زىت كەلگەندە يۇقىرى HE4 تېستىنى تەكرارلاش پايدىلىق بولىدۇ. تەكرار تەكشۈرۈش ياخشى بولسا بىرلا تەجرىبىخانىدا ئېلىپ بېرىلىشى ۋە شۇ كۈنىدىلا كرېئاتىنىن ۋە eGFR نى ئۆز ئىچىگە ئېلىشى كېرەك. 10 دىن 20 pmol/L غىچە بولغان پەرق كېسىش نۇقتىسىغا يېقىن بولسا ئادەتتىكى ئۆزگىرىشنى ئەكس ئەتتۈرۈشى مۇمكىن، ئەمما مۇقىم بۆرەك ئىقتىدارى بىلەن داۋاملىق ئېشىش تېخىمۇ كۆڭۈل بۆلۈشنى تەلەپ قىلىدۇ. تەكرار نەتىجىنىڭ قانداق قارارغا يېتەكچىلىك قىلىشىنى سىزنىڭ كىلىنكىلىق خادىمىڭىز ئېنىقلىشى كېرەك.
بۈگۈنلا AI بىلەن قان تەكشۈرۈش تەھلىلى ئېلىڭ
دۇنيادىكى 2 مىليوندىن ئارتۇق ئىشلەتكۈچى Kantesti نى دەرھال، توغرا تەجرىبىخانا تەھلىلى ئۈچۈن ئىشەنچ قىلىدۇ. قان تەكشۈرۈش نەتىجىڭىزنى يوللاپ، 15,000+ بىئوماركىرلىرىنىڭ تولۇق چۈشەندۈرۈشىنى بىر نەچچە سېكۇنتتا ئېلىڭ.
📚 پايدىلىنىلغان تەتقىقات ئېلانلىرى
Klein, T., Mitchell, S., & Weber, H. (2026). سۈيدۈك تەكشۈرۈشىدىكى Urobilinogen: 2026 تولۇق سۈيدۈك تەكشۈرۈش قوللانمىسى. Kantesti AI Medical Research.
Klein, T., Mitchell, S., & Weber, H. (2026). تۆمۈر تەتقىقات قوللانمىسى: TIBC، تۆمۈرنىڭ تويۇنۇش دەرىجىسى ۋە باغلىنىش ئىقتىدارى. Kantesti AI Medical Research.
📖 تاشقى داۋالاش پايدىلىنىش ماتېرىياللىرى
ACOG Committee on Practice Bulletins—Gynecology (2016). Practice Bulletin No. 174: Evaluation and Management of Adnexal Masses. «Obstetrics & Gynecology».
⚕️ تېببىي ئەسكەرتىش
بۇ ماقالە پەقەت تەربىيە-ئوقۇتۇش مەقسىتى ئۈچۈن بولۇپ، داۋالاش مەسلىھەتىنى تەشكىل قىلمايدۇ. دىئاگنوز قويۇش ۋە داۋالاش قارارلىرى ئۈچۈن ھەمىشە لاياقەتلىك ساغلاملىق مۇلازىمىتى تەمىنلىگۈچى بىلەن مەسلىھەتلىشىڭ.
E-E-A-T ئىشەنچ سىگناللىرى
تەجرىبە
دوختۇر رەھبەرلىكىدىكى لابوراتورىيە تەبىرىنى چۈشەندۈرۈش خىزمەت ئېقىملىرىنى بالىياتقۇچلۇق تەكشۈرۈش.
مۇتەخەسسىسلىك
بىئوماركىرلارنىڭ كىلىنىكىلىق مۇھىتتا قانداق ھەرىكەت قىلىدىغانلىقىغا مەركەزلەشكەن لابوراتورىيە تېبابىتى.
ھوقۇقدارلىق
دوكتور توماس كلېين تەرىپىدىن يېزىلغان، دوكتور سارا ميتچېل ۋە پروف. دوكتور ھانس ۋېبېر تەرىپىدىن تەكشۈرۈلگەن.
ئىشەنچلىكلىك
ئاگاھلاندۇرۇشنى ئازايتىش ئۈچۈن ئېنىق كېيىنكى قەدەملەر بىلەن ئىسپات-ئاساسلىق تەبىر.